ClinicalTrials.gg
CompletedNCT02755597BelliniUpdated Aug 22, 2023Results posted

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

A Phase 3 interventional study of Venetoclax and Bortezomib in Relapsed/Refractory Multiple Myeloma, sponsored by AbbVie. Completed at 97 sites in 16 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-08-22.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
291
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing venetoclax in Multiple Myeloma — 4 open to participants now, 9 under way, 2 of them phase 3. venetoclax · Multiple Myeloma.

Enrollment
Largest of 20
291 · median 42
Started
2016
the only one that year
Phase 3
3 of 20
none open now
Registered
4th of 20
by date
Lead sponsor
10 of 20
AbbVie

Among the 20 studies testing venetoclax in Multiple Myeloma, this one has the largest enrollment, is the only one that started in 2016, is one of 3 in phase 3, and was the 4th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

4 of the 20 studies testing venetoclax in Multiple Myeloma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing venetoclax in Multiple Myeloma, or all of them as a file.
02

Study summary

This was a Phase 3, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and received 1 to 3 prior lines of therapy for multiple myeloma.

03

Conditions studied

  • Relapsed/Refractory Multiple Myeloma

Browse trials for

Keywords

  • Relapsed/refractory multiple myeloma
  • Relapsed multiple myeloma
  • Refractory multiple myeloma
  • Multiple myeloma
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance score ≤ 2
  • Participant has documented or progressive multiple myeloma on or after any regimen or who are refractory to the most recent . Relapsed myeloma is defined as previously treated myeloma that progresses and requires initiation of salvage therapy, but does not meet the criteria for refractory myeloma. Refractory myeloma is defined as disease that is nonresponsive (failure to achieve minimal response or development of progressive disease [PD]) while on primary or salvage therapy, or progresses within 60 days of last therapy.
  • Participant must have received prior treatment with at least one, but no more than three, prior lines of therapy for multiple myeloma. A line of therapy consists of ≥ 1 complete cycle of a single agent, a regimen consisting of combination of several drugs, or a planned sequential therapy of various regimens.
  • Prior treatment with bortezomib or other proteasome inhibitor is allowed, provided ALL of the following criteria are met: Disease is NOT refractory to any proteasome inhibitor, defined as no disease progression (i.e., PD, per International Myeloma Working Group [IMWG] or European Society for Blood and Marrow Transplantation [EBMT] criteria) while receiving proteasome inhibitor therapy or within 60 days after the last dose, AND best response achieved with any proteasome inhibitor therapy (alone or in combination) was at least a Partial Response (PR), AND participant did not discontinue any proteasome inhibitor due to intolerance or ≥ Grade 3 related toxicity.
  • Participant has at Screening, defined as at least one of the following: Serum M-protein ≥ 0.5 g/dL, OR Urine M-protein ≥ 200 mg in 24-hours, OR serum immunoglobulin free light chain (FLC) ≥ 10 mg/dL provided serum FLC ratio is abnormal.

Exclusion criteria

Exclusion Criteria:

  • Participant is to any proteasome inhibitor, defined as progression on or within 60 days of the last dose of a proteasome inhibitor-containing regimen.
  • Participant has had prior treatment with proteasome inhibitor within 60 days prior to first dose of study drug.
  • Participant has any of the following conditions:

Non-secretory multiple myeloma, active plasma cell leukemia i.e., either 20% of peripheral white blood cells or greater than 2.0 X 10\^9/liter (L) circulating plasma cells by standard differential, Waldenstrom's macroglobulinemia, amyloidosis, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), known Human Immunodeficiency Viral () infection, active or C infection based on blood screen tests, significant cardiovascular disease, including uncontrolled angina, severe or uncontrolled arrhythmia, recent myocardial infarction within 6 months of randomization, or congestive heart failure (NYHA) Class ≥ 3, major surgery within 4 weeks prior to randomization, acute infections requiring parenteral therapy (antibiotic, antifungal, or antiviral) within 14 days prior to randomization, peripheral neuropathy ≥ Grade 3 or ≥ Grade 2 with pain within 2 weeks prior to randomization, uncontrolled diabetes or uncontrolled hypertension within 14 days prior to randomization, any other medical condition that, in the opinion of the Investigator, would adversely affect the participant's participation in the study

  • Participant has a history of other active , including myelodysplastic syndrome (MDS), within the past 3 years prior to study entry, with the following exceptions: Adequately treated in situ carcinoma of the cervix uteri or the breast, basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin, prostate cancer Gleason grade 6 or lower AND with stable Prostate Specific Antigen (PSA) levels off treatment, previous malignancy with no evidence of disease confined and surgically resected (or treated with other modalities) with curative intent and unlikely to impact survival during the duration of the study
  • If participant had prior stem cell transplant (SCT), participant has evidence of ongoing (GvHD)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
291 participants (actual)

Study arms

  • Experimental
    Venetoclax + Bortezomib and Dexamethasone

    Cycles 1-8: Venetoclax 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\^2 subcutaneously or IV on Days 1, 4, 8 \& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \& 12; Cycles 9 and beyond: Venetoclax 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 and 23

    Drug: Venetoclax · Drug: Bortezomib · Drug: Dexamethasone

  • Placebo comparator
    Placebo + Bortezomib and Dexamethasone

    Cycles 1-8: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\^2 subcutaneously or IV on Days 1, 4, 8 \& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \& 12; Cycles 9 and beyond: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 \& 23

    Drug: Bortezomib · Drug: Dexamethasone · Drug: Placebo for venetoclax

Interventions

  • Participants self-administered venetoclax tablets by mouth QD in combination with bortezomib. Venetoclax was to be given before other agents administered on the same day, if applicable. Each venetoclax dose was to be taken all at one time with approximately 240 mL of water within 30 minutes after completion of breakfast or the subject's first meal of the day. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed. On days that pre-dose PK sampling was required, dosing occurred at the clinic to facilitate PK sampling.

    Also known as: VENCLEXTA, VENCLYXTO

  • Bortezomib (subcutaneous injection \[preferred\] or IV) was given following administration of venetoclax or placebo in Cycles 1 -8 on Days 1, 4, 8 and 11, and for Cycles 9 and beyond, on Days 1, 8, 15 and 22 and was to be administered per the prescribing information. The route of administration was to stay the same during the study.

    Also known as: Velcade

  • Dexamethasone was to be given orally, administered per the prescribing information, the day of bortezomib dosing and the following day, given the protocol-defined dosing window (bortezomib dosing window is ± 1 day) is maintained. If bortezomib was interrupted or a dose is skipped, dexamethasone was to be administered as scheduled per protocol (unless dexamethasone was interrupted due to toxicity).

  • DrugPlacebo for venetoclax

    Participants self-administered placebo tablets by mouth QD in combination with bortezomib. Placebo was to be given before other agents administered on the same day, if applicable. Each placebo dose was to be taken all at one time with approximately 240 mL of water within 30 minutes after completion of breakfast or the subject's first meal of the day. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed. On days that pre-dose PK sampling was required, dosing occurred at the clinic to facilitate PK sampling.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS is defined as the number of days from the date the participant was randomized to the date of the first documented progressive disease (PD) as determined by an Independent Review Committee (IRC) or death due to any cause, whichever occurs first. PFS was analyzed by Kaplan-Meier methodology.

    Time frame: Median duration of follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group

Secondary outcomes

  1. Very Good Partial Response (VGPR) or Better Response Rate

    The percentage of participants with documented best overall response of Very Good Partial Response (VGPR) or better (VGPR, Complete response \[CR\], or Stringent complete response \[sCR\]) per 2016 standard International Myeloma Working Group (IMWG) criteria as determined by an Independent Review Committee (IRC) was computed.

    Time frame: Response was assessed at Cycle 1, Day 1, and on Day 1 of every cycle thereafter; median time on follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group

  2. Progression-Free Survival (PFS) in Participants With High B-cell Lymphoma 2 (BCL-2) Expression

    PFS is defined as the number of days from the date the participant was randomized to the date of the first documented progressive disease (PD) per investigator assessment or death due to any cause, whichever occurs first. PFS was analyzed by Kaplan-Meier methodology. BCL-2 expression was determined through central laboratory testing by immunohistochemistry (IHC) and based on a pre-specified scoring algorithm. High clinical score of 2+: ≥50% of tumor cells with moderate or higher cytoplasmic staining but \< 50% of tumor cells with strong staining intensity; high clinical score of 3+: ≥50% of tumor cells with strong cytoplasmic staining.

    Time frame: Median duration of follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group

  3. Duration of Response (DOR)

    DOR is defined as the number of days from the participant's date of first documented response (partial response \[PR\] or better) to the date of first documented progressive disease (PD) as determined by an Independent Review Committee (IRC) or death due to multiple myeloma, whichever occurs first. DOR was analyzed by Kaplan-Meier methodology.

    Time frame: Response was assessed at Cycle 1, Day 1, and on Day 1 of every cycle thereafter; median time on follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group

  4. Mean Change From Baseline in Brief Pain Inventory - Short Form (BPI-SF) Worst Pain

    The BPI-SF is a pain-specific measure developed to assess patient-reported severity (or intensity) of pain (4 items) and the impact of pain on daily functioning (7 items) in patients with cancer pain. The four pain severity items assess pain at its "worst in last 24 hours," "least in last 24 hours," "average," and "now" (current pain). For these items, participants are asked to rate their pain on an 11-point numeric rating scale with anchors of 0 (no pain) and 10 (pain as bad as you can imagine). The Worst Pain scores range from 0 to 10, with higher scores indicating severe pain. Negative changes from baseline indicate improvement.

    Time frame: Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment

  5. Mean Change From Baseline in Physical Functioning Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Physical Functioning scale, participants rate five items on a four-point scale, with 1 as "not at all" and 4 as "very much." The Physical Functioning Scale scores range from 0 to 100 and were calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high scale score represents high/healthy level of functioning. Positive changes from baseline indicate improvement.

    Time frame: Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment

  6. Mean Change From Baseline in Global Health Status/Quality of Life Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Global Health Status/Quality of Life scale, participants rate two items on a seven point scale, with 1 as "very poor" and 7 as "excellent." The Global Health Status/Quality of Life scale ranges from 0 to 100 and was calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high score for the global health status/QoL represents a high QoL. Positive changes from baseline indicate improvement.

    Time frame: Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment

  7. Mean Change From Baseline in Patient Reported Outcomes Measurement Information System [PROMIS] Cancer Fatigue Short Form [SF] Score

    PROMIS Cancer Fatigue SF is a seven item questionnaire that assesses the impact and experience of fatigue over the past 7 days. All questions employ the following five response options: 1 = Not at all, 2 = A little bit, 3 = Somewhat, 4 = Quite a bit, and 5 = Very much. The total raw score is the sum of the responses to each question and is converted to a T-score. The T-score re-scales the total raw score to a standardized score with a mean of 50 and a standard deviation of 10. The \[PROMIS\] Cancer Fatigue Short Form \[SF\] 7a T-Scores range from 29.4 to 83.2, with higher scores indicating more fatigue. Negative changes from baseline indicate improvement.

    Time frame: Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment

  8. Overall Survival (OS).

    OS is defined as the number of days from the date of randomization to the date of death due to any cause. All events of death were to be included, regardless of whether the event occurred while the participant was still taking study drug or after the participant discontinued study drug. If a participant is not known to have died, OS was censored at the date of last contact. The distribution of OS was estimated using Kaplan-Meier methodology.

    Time frame: Median duration of follow-up was 45.6 months for the venetoclax group and 45.6 months for the placebo group

  9. Time to Progression (TTP)

    TTP is defined as the number of days from the date of randomization to the date of first documented progressive disease (PD) as determined by an Independent Review Committee (IRC) or death due to multiple myeloma, whichever occurs first. TTP was analyzed by Kaplan-Meier methodology.

    Time frame: Median time on follow-up up was 28.6 months for the venetoclax group and 28.6 months for the placebo group

  10. Overall Response Rate (ORR)

    Overall response rate is defined as the percentage of participants with documented best overall response of Partial Response (PR) or better (PR, Very good partial response \[VGPR\], Complete response \[CR\], or Stringent complete response \[sCR\]) per International Myeloma Working Group (IMWG) criteria as determined by an Independent Review Committee (IRC).

    Time frame: Response was assessed at Cycle 1, Day 1, and on Day 1 of every cycle thereafter; median time on follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group

  11. Minimal Residual Disease (MRD) Negativity Rate

    MRD negativity rate is defined as the percentage of participants who have negative MRD by bone marrow aspirate at any time point after randomization and before progression or starting subsequent therapy. MRD negativity was defined at 10\^-5 threshold (less than one residual myeloma cell per 10\^5 total nucleated cells) as measured by centralized testing of bone marrow aspirate by Next Generation Sequencing (NGS). MRD positive participants include those of which all tested samples were found to be MRD positive or indeterminate. Participants with missing or unevaluable MRD status were considered as MRD positive.

    Time frame: Assessed at Screening; to confirm a stringent Complete Response (sCR) or Complete Response (CR); at 6 months and 12 months post-confirmed CR/sCR

07

Results

Posted Aug 22, 2023

Participant flow

Participant flow — Overall Study
MilestoneVenetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and Dexamethasone
Started19497
Completed00
Not completed19497
Withdrew: Withdrew consent2711
Withdrew: Lost to follow-up10
Withdrew: Death7836
Withdrew: Study terminated by sponsor6747
Withdrew: Other, not specified203
Withdrew: Participant missing reason for study discontinuation10

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS is defined as the number of days from the date the participant was randomized to the date of the first documented progressive disease (PD) as determined by an Independent Review Committee (IRC) or death due to any cause, whichever occurs first. PFS was analyzed by Kaplan-Meier methodology.

Time frame:
Median duration of follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group
Reported as:
Median · months
Progression-free Survival (PFS)
monthsVenetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and Dexamethasone
Progression-free Survival (PFS)23.2 (15.3 to 27.5)11.5 (9.6 to 15.0)
Statistical analysis
  • Venetoclax + Bortezomib and Dexamethasone vs Placebo + Bortezomib and Dexamethasone · Log Rank · p = =0.012 · Hazard ratio (hr): 0.656 · 95% CI 0.471 to 0.913Hazard ratio was estimated by Cox proportional hazards model
SecondaryVery Good Partial Response (VGPR) or Better Response Rate

The percentage of participants with documented best overall response of Very Good Partial Response (VGPR) or better (VGPR, Complete response \[CR\], or Stringent complete response \[sCR\]) per 2016 standard International Myeloma Working Group (IMWG) criteria as determined by an Independent Review Committee (IRC) was computed.

Time frame:
Response was assessed at Cycle 1, Day 1, and on Day 1 of every cycle thereafter; median time on follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group
Reported as:
Number · percentage of participants
Very Good Partial Response (VGPR) or Better Response Rate
percentage of participantsVenetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and Dexamethasone
Very Good Partial Response (VGPR) or Better Response Rate60.3 (53.1 to 67.2)38.1 (28.5 to 48.6)
Statistical analysis
  • Venetoclax + Bortezomib and Dexamethasone vs Placebo + Bortezomib and Dexamethasone · Cochran-Mantel-Haenszel · p = <0.001
SecondaryProgression-Free Survival (PFS) in Participants With High B-cell Lymphoma 2 (BCL-2) Expression

PFS is defined as the number of days from the date the participant was randomized to the date of the first documented progressive disease (PD) per investigator assessment or death due to any cause, whichever occurs first. PFS was analyzed by Kaplan-Meier methodology. BCL-2 expression was determined through central laboratory testing by immunohistochemistry (IHC) and based on a pre-specified scoring algorithm. High clinical score of 2+: ≥50% of tumor cells with moderate or higher cytoplasmic staining but \< 50% of tumor cells with strong staining intensity; high clinical score of 3+: ≥50% of tumor cells with strong cytoplasmic staining.

Time frame:
Median duration of follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group
Reported as:
Median · months
Progression-Free Survival (PFS) in Participants With High B-cell Lymphoma 2 (BCL-2) Expression
monthsVenetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and Dexamethasone
Progression-Free Survival (PFS) in Participants With High B-cell Lymphoma 2 (BCL-2) Expression23.8 (19.5 to 34.7)11.4 (9.1 to 15.0)
SecondaryDuration of Response (DOR)

DOR is defined as the number of days from the participant's date of first documented response (partial response \[PR\] or better) to the date of first documented progressive disease (PD) as determined by an Independent Review Committee (IRC) or death due to multiple myeloma, whichever occurs first. DOR was analyzed by Kaplan-Meier methodology.

Time frame:
Response was assessed at Cycle 1, Day 1, and on Day 1 of every cycle thereafter; median time on follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group
Reported as:
Median · months
Duration of Response (DOR)
monthsVenetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and Dexamethasone
Duration of Response (DOR)NA (22.8 to NA)12.8 (10.6 to 15.5)
Statistical analysis
  • Venetoclax + Bortezomib and Dexamethasone vs Placebo + Bortezomib and Dexamethasone · Log Rank · p = <0.001 · Hazard ratio (hr): 0.508 · 95% CI 0.343 to 0.753Hazard ratio was estimated by Cox proportional hazards model
SecondaryMean Change From Baseline in Brief Pain Inventory - Short Form (BPI-SF) Worst Pain

The BPI-SF is a pain-specific measure developed to assess patient-reported severity (or intensity) of pain (4 items) and the impact of pain on daily functioning (7 items) in patients with cancer pain. The four pain severity items assess pain at its "worst in last 24 hours," "least in last 24 hours," "average," and "now" (current pain). For these items, participants are asked to rate their pain on an 11-point numeric rating scale with anchors of 0 (no pain) and 10 (pain as bad as you can imagine). The Worst Pain scores range from 0 to 10, with higher scores indicating severe pain. Negative changes from baseline indicate improvement.

Time frame:
Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment
Reported as:
Mean · units on a scale
Mean Change From Baseline in Brief Pain Inventory - Short Form (BPI-SF) Worst Pain
units on a scaleVenetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and Dexamethasone
Cycle 3, Day 1-0.6 ± 2.59-0.5 ± 2.46
Cycle 5, Day 10.0 ± 2.65-0.2 ± 3.15
Cycle 7, Day 1-0.1 ± 2.560.2 ± 2.98
Cycle 9, Day 1-0.2 ± 3.110.0 ± 2.88
Cycle 11, Day 1-0.4 ± 2.570.1 ± 3.45
Cycle 13, Day 1-0.2 ± 2.71-0.1 ± 3.22
Cycle 15, Day 1-0.2 ± 2.92-0.0 ± 3.08
Cycle 17, Day 1-0.3 ± 2.54-0.1 ± 2.06
Cycle 19, Day 1-0.1 ± 2.59-0.2 ± 1.95
Cycle 21, Day 1-0.1 ± 2.39-0.3 ± 2.89
Cycle 23, Day 1-0.0 ± 3.20-0.2 ± 2.61
Cycle 25, Day 10.4 ± 2.650.2 ± 3.00
Cycle 27, Day 10.2 ± 2.530.1 ± 1.92
Cycle 29, Day 1-0.2 ± 2.830.3 ± 2.15
Cycle 31, Day 10.0 ± 3.110.6 ± 1.33
Cycle 33, Day 1-0.2 ± 2.880.4 ± 1.40
Cycle 35, Day 10.1 ± 2.77-0.2 ± 1.33
Cycle 37, Day 10.4 ± 2.781.5 ± 2.65
Cycle 39, Day 10.1 ± 2.70-0.3 ± 1.15
Cycle 41, Day 10.1 ± 3.000.3 ± 1.15
Cycle 43, Day 1-0.1 ± 3.070.5 ± 0.71
Cycle 45, Day 1-0.7 ± 3.641.0 ± 0.00
Cycle 47, Day 1-2.8 ± 3.771.0
Final visit0.3 ± 3.280.4 ± 3.55
SecondaryMean Change From Baseline in Physical Functioning Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Physical Functioning scale, participants rate five items on a four-point scale, with 1 as "not at all" and 4 as "very much." The Physical Functioning Scale scores range from 0 to 100 and were calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high scale score represents high/healthy level of functioning. Positive changes from baseline indicate improvement.

Time frame:
Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment
Reported as:
Mean · units on a scale
Mean Change From Baseline in Physical Functioning Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
units on a scaleVenetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and Dexamethasone
Cycle 3, Day 1-5.0 ± 18.22-4.6 ± 19.50
Cycle 5, Day 1-3.9 ± 18.38-7.8 ± 21.50
Cycle 7, Day 1-6.1 ± 20.19-8.6 ± 19.76
Cycle 9, Day 1-3.5 ± 19.54-8.0 ± 20.01
Cycle 11, Day 1-1.5 ± 15.92-7.5 ± 18.46
Cycle 13, Day 1-3.2 ± 16.57-8.8 ± 22.85
Cycle 15, Day 1-2.3 ± 18.72-7.3 ± 22.27
Cycle 17, Day 1-1.8 ± 16.23-8.6 ± 19.90
Cycle 19, Day 1-2.5 ± 19.30-7.0 ± 19.35
Cycle 21, Day 1-1.5 ± 17.81-8.5 ± 20.43
Cycle 23, Day 1-3.4 ± 20.32-7.5 ± 20.53
Cycle 25, Day 1-3.8 ± 17.280.5 ± 23.95
Cycle 27, Day 1-8.6 ± 21.69-3.3 ± 18.44
Cycle 29, Day 1-8.7 ± 21.25-4.0 ± 19.81
Cycle 31, Day 1-2.8 ± 17.982.2 ± 18.56
Cycle 33, Day 1-4.0 ± 22.76-4.8 ± 23.64
Cycle 35, Day 1-7.0 ± 16.644.4 ± 18.70
Cycle 37, Day 1-7.5 ± 22.4915.0 ± 14.78
Cycle 39, Day 1-10.1 ± 18.808.9 ± 10.18
Cycle 41, Day 1-13.0 ± 25.6513.3 ± 23.09
Cycle 43, Day 1-7.8 ± 23.1213.3 ± 18.86
Cycle 45, Day 1-1.3 ± 10.3313.3 ± 18.86
Cycle 47, Day 10.0 ± 14.400.0
Final visit-11.8 ± 22.85-10.0 ± 21.52
SecondaryMean Change From Baseline in Global Health Status/Quality of Life Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Global Health Status/Quality of Life scale, participants rate two items on a seven point scale, with 1 as "very poor" and 7 as "excellent." The Global Health Status/Quality of Life scale ranges from 0 to 100 and was calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high score for the global health status/QoL represents a high QoL. Positive changes from baseline indicate improvement.

Time frame:
Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment
Reported as:
Mean · units on a scale
Mean Change From Baseline in Global Health Status/Quality of Life Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
units on a scaleVenetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and Dexamethasone
Cycle 3, Day 1-1.9 ± 22.75-2.2 ± 22.63
Cycle 5, Day 1-5.1 ± 26.74-2.5 ± 23.54
Cycle 7, Day 1-8.3 ± 26.76-6.7 ± 24.56
Cycle 9, Day 1-6.9 ± 26.33-6.7 ± 24.22
Cycle 11, Day 1-0.5 ± 25.58-5.2 ± 25.38
Cycle 13, Day 1-1.0 ± 25.05-1.7 ± 22.24
Cycle 15, Day 1-4.9 ± 26.090.5 ± 23.56
Cycle 17, Day 1-5.1 ± 24.91-7.7 ± 21.55
Cycle 19, Day 1-1.3 ± 19.510.8 ± 26.09
Cycle 21, Day 1-6.6 ± 26.16-5.6 ± 20.01
Cycle 23, Day 1-2.9 ± 23.20-1.0 ± 22.99
Cycle 25, Day 1-4.7 ± 26.29-4.5 ± 24.68
Cycle 27, Day 1-9.0 ± 24.464.2 ± 26.70
Cycle 29, Day 1-6.9 ± 24.67-1.1 ± 26.33
Cycle 31, Day 1-4.8 ± 26.485.6 ± 35.36
Cycle 33, Day 1-7.7 ± 27.22-7.1 ± 22.79
Cycle 35, Day 1-3.8 ± 24.034.2 ± 29.23
Cycle 37, Day 1-13.7 ± 29.8610.4 ± 12.50
Cycle 39, Day 1-9.3 ± 28.050.0 ± 0.00
Cycle 41, Day 1-11.0 ± 30.478.3 ± 8.33
Cycle 43, Day 12.0 ± 28.95-8.3 ± 23.57
Cycle 45, Day 1-1.7 ± 33.754.2 ± 5.89
Cycle 47, Day 110.4 ± 22.95-8.3
Final visit-8.1 ± 26.40-6.7 ± 28.50
SecondaryMean Change From Baseline in Patient Reported Outcomes Measurement Information System [PROMIS] Cancer Fatigue Short Form [SF] Score

PROMIS Cancer Fatigue SF is a seven item questionnaire that assesses the impact and experience of fatigue over the past 7 days. All questions employ the following five response options: 1 = Not at all, 2 = A little bit, 3 = Somewhat, 4 = Quite a bit, and 5 = Very much. The total raw score is the sum of the responses to each question and is converted to a T-score. The T-score re-scales the total raw score to a standardized score with a mean of 50 and a standard deviation of 10. The \[PROMIS\] Cancer Fatigue Short Form \[SF\] 7a T-Scores range from 29.4 to 83.2, with higher scores indicating more fatigue. Negative changes from baseline indicate improvement.

Time frame:
Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment
Reported as:
Mean · T-score
Mean Change From Baseline in Patient Reported Outcomes Measurement Information System [PROMIS] Cancer Fatigue Short Form [SF] Score
T-scoreVenetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and Dexamethasone
Cycle 3, Day 12.2 ± 9.541.8 ± 8.12
Cycle 5, Day 13.3 ± 9.252.4 ± 10.34
Cycle 7, Day 13.2 ± 9.282.6 ± 9.70
Cycle 9, Day 12.3 ± 8.902.6 ± 8.67
Cycle 11, Day 10.6 ± 8.543.1 ± 8.98
Cycle 13, Day 11.8 ± 8.032.3 ± 6.97
Cycle 15, Day 11.5 ± 8.842.1 ± 7.66
Cycle 17, Day 11.2 ± 8.112.6 ± 8.05
Cycle 19, Day 10.7 ± 8.520.9 ± 9.32
Cycle 21, Day 11.6 ± 8.581.2 ± 7.66
Cycle 23, Day 12.0 ± 8.081.5 ± 8.83
Cycle 25, Day 12.0 ± 8.59-0.1 ± 8.73
Cycle 27, Day 13.4 ± 8.19-0.1 ± 9.59
Cycle 29, Day 13.9 ± 8.070.8 ± 8.51
Cycle 31, Day 12.8 ± 8.43-0.3 ± 9.15
Cycle 33, Day 12.0 ± 8.933.7 ± 9.17
Cycle 35, Day 13.4 ± 9.271.1 ± 7.22
Cycle 37, Day 14.1 ± 9.72-3.0 ± 11.72
Cycle 39, Day 13.6 ± 8.124.1 ± 2.82
Cycle 41, Day 13.3 ± 8.69-0.7 ± 6.90
Cycle 43, Day 15.3 ± 9.284.4 ± 1.91
Cycle 45, Day 1-0.3 ± 7.991.8 ± 0.28
Cycle 47, Day 1-2.5 ± 6.300.0
Final visit5.0 ± 10.952.9 ± 9.96
SecondaryOverall Survival (OS).

OS is defined as the number of days from the date of randomization to the date of death due to any cause. All events of death were to be included, regardless of whether the event occurred while the participant was still taking study drug or after the participant discontinued study drug. If a participant is not known to have died, OS was censored at the date of last contact. The distribution of OS was estimated using Kaplan-Meier methodology.

Time frame:
Median duration of follow-up was 45.6 months for the venetoclax group and 45.6 months for the placebo group
Reported as:
Median · months
Overall Survival (OS).
monthsVenetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and Dexamethasone
Overall Survival (OS).NA (44.4 to NA)NA (44.0 to NA)
Statistical analysis
  • Venetoclax + Bortezomib and Dexamethasone vs Placebo + Bortezomib and Dexamethasone · Log Rank · p = =0.385 · Hazard ratio (hr): 1.191 · 95% CI 0.802 to 1.770Hazard ratio was estimated by Cox proportional hazards model
SecondaryTime to Progression (TTP)

TTP is defined as the number of days from the date of randomization to the date of first documented progressive disease (PD) as determined by an Independent Review Committee (IRC) or death due to multiple myeloma, whichever occurs first. TTP was analyzed by Kaplan-Meier methodology.

Time frame:
Median time on follow-up up was 28.6 months for the venetoclax group and 28.6 months for the placebo group
Reported as:
Median · months
Time to Progression (TTP)
monthsVenetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and Dexamethasone
Time to Progression (TTP)25.4 (20.6 to NA)12.2 (9.9 to 15.0)
Statistical analysis
  • Venetoclax + Bortezomib and Dexamethasone vs Placebo + Bortezomib and Dexamethasone · Log Rank · p = =0.001 · Hazard ratio (hr): 0.571 · 95% CI 0.405 to 0.805Hazard ratio was estimated by Cox proportional hazards model
SecondaryOverall Response Rate (ORR)

Overall response rate is defined as the percentage of participants with documented best overall response of Partial Response (PR) or better (PR, Very good partial response \[VGPR\], Complete response \[CR\], or Stringent complete response \[sCR\]) per International Myeloma Working Group (IMWG) criteria as determined by an Independent Review Committee (IRC).

Time frame:
Response was assessed at Cycle 1, Day 1, and on Day 1 of every cycle thereafter; median time on follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsVenetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and Dexamethasone
Overall Response Rate (ORR)81.4 (75.2 to 86.7)69.1 (58.9 to 78.1)
Statistical analysis
  • Venetoclax + Bortezomib and Dexamethasone vs Placebo + Bortezomib and Dexamethasone · Cochran-Mantel-Haenszel · p = =0.019
SecondaryMinimal Residual Disease (MRD) Negativity Rate

MRD negativity rate is defined as the percentage of participants who have negative MRD by bone marrow aspirate at any time point after randomization and before progression or starting subsequent therapy. MRD negativity was defined at 10\^-5 threshold (less than one residual myeloma cell per 10\^5 total nucleated cells) as measured by centralized testing of bone marrow aspirate by Next Generation Sequencing (NGS). MRD positive participants include those of which all tested samples were found to be MRD positive or indeterminate. Participants with missing or unevaluable MRD status were considered as MRD positive.

Time frame:
Assessed at Screening; to confirm a stringent Complete Response (sCR) or Complete Response (CR); at 6 months and 12 months post-confirmed CR/sCR
Reported as:
Number · percentage of participants
Minimal Residual Disease (MRD) Negativity Rate
percentage of participantsVenetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and Dexamethasone
Minimal Residual Disease (MRD) Negativity Rate15.5 (10.7 to 21.3)2.1 (0.3 to 7.3)
Statistical analysis
  • Venetoclax + Bortezomib and Dexamethasone vs Placebo + Bortezomib and Dexamethasone · Cochran-Mantel-Haenszel · p = <0.001

Adverse events

Collected over All-cause mortality is reported from enrollment to end of study; median time on follow-up was 48.4 months for the venetoclax group and 47.2 months for the placebo group. TEAEs and SAEs were collected from first dose of study drug until 30 days after last dose of study drug; mean time on venetoclax was 582.2 days and mean time on placebo was 431.3 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Venetoclax + Bortezomib and Dexamethasone81/194 (41.8%)115/193 (59.6%)191/193 (99%)
Placebo + Bortezomib and Dexamethasone36/97 (37.1%)53/96 (55.2%)95/96 (99%)
Most frequent serious events
Showing 10 of 154
Most frequent serious events
EventVenetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and Dexamethasone
PNEUMONIAInfections and infestations35/19314/96
LOWER RESPIRATORY TRACT INFECTIONInfections and infestations4/1935/96
INFLUENZAInfections and infestations3/1934/96
CATARACTEye disorders3/1933/96
FEMUR FRACTUREInjury, poisoning and procedural complications3/1933/96
ACUTE KIDNEY INJURYRenal and urinary disorders3/1933/96
FEBRILE NEUTROPENIABlood and lymphatic system disorders6/1930/96
COVID-19 PNEUMONIAInfections and infestations6/1931/96
SEPSISInfections and infestations6/1930/96
ORTHOSTATIC HYPOTENSIONVascular disorders5/1932/96
Most frequent other events
Showing 10 of 81
Most frequent other events
EventVenetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and Dexamethasone
DIARRHOEAGastrointestinal disorders114/19346/96
NAUSEAGastrointestinal disorders73/19322/96
THROMBOCYTOPENIABlood and lymphatic system disorders53/19334/96
CONSTIPATIONGastrointestinal disorders68/19329/96
FATIGUEGeneral disorders63/19331/96
NEUROPATHY PERIPHERALNervous system disorders59/19327/96
INSOMNIAPsychiatric disorders56/19329/96
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations55/19325/96
NEUTROPENIABlood and lymphatic system disorders54/1939/96
PERIPHERAL SENSORY NEUROPATHYNervous system disorders36/19324/96

Baseline characteristics

Intent-To-Treat (ITT) analysis set: all randomized participants, analyzed by treatment group assignment given at the time of randomization

Age, Continuous
Age, Continuous(years)Venetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and DexamethasoneTotal
Mean65.9 ± 9.4165.9 ± 7.8165.9 ± 8.90
Sex: Female, Male
Sex: Female, Male(Participants)Venetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and DexamethasoneTotal
Female9742139
Male9755152
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Venetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and DexamethasoneTotal
Hispanic or Latino25732
Not Hispanic or Latino16990259
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Venetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and DexamethasoneTotal
American Indian or Alaska Native000
Asian592887
Native Hawaiian or Other Pacific Islander000
Black or African American9312
White12466190
More than one race202
Unknown or Not Reported000
Time since diagnosis
Time since diagnosis(days)Venetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and DexamethasoneTotal
Median1263.5 (62.0 to 8356.0)1461.0 (195.0 to 4906.0)1318.0 (62.0 to 8356.0)
Number of prior lines of therapy
Number of prior lines of therapy(number of prior lines of therapy)Venetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and DexamethasoneTotal
Median1.0 (1.0 to 3.0)2.0 (1.0 to 3.0)1.0 (1.0 to 3.0)
Number of prior lines of multiple myeloma therapy
Number of prior lines of multiple myeloma therapy(Participants)Venetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and DexamethasoneTotal
1 line9144135
2-3 lines10353156
Prior exposure to proteasome inhibitors (PI)
Prior exposure to proteasome inhibitors (PI)(Participants)Venetoclax + Bortezomib and DexamethasonePlacebo + Bortezomib and DexamethasoneTotal
Refractory022
Sensitive13166197
Naïve612889
Unknown202
MISSING011

5 further baseline measures are reported on the registry.

08

Study locations

97 sites
  • Rocky Mountain Regional VA Medical Center/Eastern Colorado Health Care System /ID# 156524
    Aurora, Colorado 80045, United States
  • Univ of Colorado Cancer Center /ID# 149130
    Aurora, Colorado 80045, United States
  • Duke Cancer Center /ID# 149099
    Durham, North Carolina 27710-3000, United States
  • Gabrail Cancer Center Research /ID# 149098
    Canton, Ohio 44718, United States
  • Royal Prince Alfred Hospital /ID# 149108
    Camperdown, New South Wales 2050, Australia
  • Concord Repatriation General Hospital /ID# 149106
    Concord, New South Wales 2139, Australia
  • Liverpool Hospital /ID# 149110
    Liverpool, New South Wales 2170, Australia
  • Royal Brisbane and Women's Hospital /ID# 149105
    Herston, Queensland 4029, Australia
  • The Queen Elizabeth Hospital /ID# 149104
    Woodville South, South Australia 5011, Australia
  • Royal Hobart Hospital /ID# 149111
    Hobart, Tasmania 7000, Australia
  • Box Hill Hospital /ID# 149112
    Box Hill, Victoria 3128, Australia
  • Peter MacCallum Cancer Ctr /ID# 149107
    Melbourne, Victoria 3000, Australia
  • Alfred Health /ID# 150085
    Melbourne, Victoria 3004, Australia
  • Fiona Stanley Hospital /ID# 148967
    Murdoch, Western Australia 6150, Australia
  • Perth Blood Institute Ltd /ID# 148966
    Nedlands, Western Australia 6009, Australia
  • Hospital das Clinicas da Universidade Federal de Goiás /ID# 149290
    Goiania, Goias 74605-020, Brazil
  • Liga Norte Riograndense Contra o Câncer /ID# 149023
    Natal, Rio Grande Do Norte 59075-740, Brazil
  • Hospital Sao Lucas da PUCRS /ID# 149027
    Porto Alegre, Rio Grande Do Sul 90610-000, Brazil
  • Clinica Sao Germano /ID# 149851
    São Paulo, Sao Paulo 04537-080, Brazil
  • Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) /ID# 149020
    Rio de Janeiro, 20231-050, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo /ID# 149025
    Sao Paulo, 05403-000, Brazil
  • Victoria Hospital /ID# 149846
    London, Ontario N6A 4L6, Canada
  • CISSS de la Monteregie /ID# 149844
    Greenfield Park, Quebec J4V 2H1, Canada
  • CHU Limoges - Dupuytren 1 /ID# 149292
    Limoges CEDEX 1, Franche-Comte 87042, France
  • CHU de Nantes, Hotel Dieu -HME /ID# 149294
    Nantes, Pays-de-la-Loire 44000, France
  • Duplicate_Centre Hospitalier Lyon Sud /ID# 149300
    Pierre Benite CEDEX, Rhone 69495, France
  • CHRU de Brest - Hopital Morvan /ID# 149299
    Brest, 29200, France
  • CHU Grenoble - Hopital Michallon /ID# 149301
    La Tronche, 38700, France
  • Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 148949
    Berlin, 10117, Germany
  • Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 148948
    Dresden, 01307, Germany
  • Asklepios Klinik Altona /ID# 150116
    Hamburg, 22763, Germany
  • Debreceni Egyetem Klinikai Kozpont /ID# 152517
    Debrecen, Hajdu-Bihar 4032, Hungary
  • Somogy Megyei Kaposi Mor Oktato Korhaz /ID# 152516
    Kaposvár, Somogy 7400, Hungary
  • Semmelweis Egyetem /ID# 152519
    Budapest, 1085, Hungary
  • Semmelweis Egyetem /ID# 152520
    Budapest, 1085, Hungary
  • Del-pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet /ID# 152518
    Budapest, 1097, Hungary
  • University Hospital Galway /ID# 149061
    Galway, H91 YR71, Ireland
  • Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 148939
    Rome, Lazio 00161, Italy
  • Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 148942
    Ancona, 60126, Italy
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna /ID# 148936
    Bologna, 40138, Italy
  • Ospedale S.Eugenio /ID# 148938
    Rome, 00144, Italy
  • A.O.U. Città della Salute e della Scienza di Torino/Ospedale Molinette /ID# 148943
    Turin, 10126, Italy
  • Nagoya City University Hospital /ID# 150943
    Nagoya shi, Aichi 467-8602, Japan
  • Kyushu University Hospital /ID# 150896
    Fukuoka-shi, Fukuoka 812-8582, Japan
  • Ogaki Municipal Hospital /ID# 150783
    Ogaki-shi, Gifu 503-8502, Japan
  • Gunma University Hospital /ID# 150275
    Maebashi-shi, Gunma 371-8511, Japan
  • National Hospital Organization Shibukawa Medical Center /ID# 150281
    Shibukawa-shi, Gunma 377-0280, Japan
  • Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital /ID# 150242
    Hiroshima-shi, Hiroshima 730-8619, Japan
  • Kobe City Medical Center General Hospital /ID# 150944
    Kobe-shi, Hyogo 650-0047, Japan
  • National Hospital Organization Mito Medical Center /ID# 151051
    Higashi Ibaraki-gun, Ibaraki 311-3193, Japan
  • Duplicate_Kyoto Prefectural University of Medicine /ID# 150719
    Kyoto-shi, Kyoto 602-8566, Japan
  • JCHO Kyoto Kuramaguchi Medical /ID# 150781
    Kyoto-shi, Kyoto 603-8151, Japan
  • Tohoku University Hospital /ID# 150945
    Sendai-shi, Miyagi 9808574, Japan
  • Okayama Medical Center /ID# 150717
    Okayama-shi, Okayama 701-1192, Japan
  • Japanese Red Cross Osaka Hospital /ID# 150716
    Osaka-shi, Osaka 543-8555, Japan
  • Saitama Medical Center /ID# 151044
    Kawagoe-shi, Saitama 350-8550, Japan
  • Tochigi Cancer Center /ID# 150192
    Utsunomiya-shi, Tochigi 320-0834, Japan
  • National Cancer Center Hospital /ID# 151039
    Chuo-ku, Tokyo 104-0045, Japan
  • The Cancer Institute Hospital Of JFCR /ID# 150780
    Koto-ku, Tokyo 135-8550, Japan
  • Japanese Red Cross Medical Center /ID# 149902
    Shibuya-ku, Tokyo 150-8935, Japan
  • National Hospital Organization Disaster Medical Center /ID# 150784
    Tachikawa-shi, Tokyo 190-0014, Japan
  • National Cancer Center /ID# 150889
    Goyang, Gyeonggido 10408, Korea, Republic of
  • Seoul National University Bundang Hospital /ID# 150888
    Seongnam, Gyeonggido 13620, Korea, Republic of
  • Duplicate_Yonsei University Health System, Severance hospital. /ID# 150891
    Seoul, Seoul Teugbyeolsi 03722, Korea, Republic of
  • Chonnam National University Hospital /ID# 150894
    Gwangju, 61469, Korea, Republic of
  • Gachon University Gil Medical Center /ID# 150893
    Incheon, 21565, Korea, Republic of
  • Seoul National University Hospital /ID# 150890
    Seoul, 03080, Korea, Republic of
  • Samsung Medical Center /ID# 150892
    Seoul, 06351, Korea, Republic of
  • The Catholic University of Korea, Seoul St. Mary's Hospital /ID# 150895
    Seoul, 06591, Korea, Republic of
  • Kuzbass Regional Clinical Hospital /ID# 148955
    Kemerovo, Kemerovskaya Oblast 650099, Russian Federation
  • State Institution of Health of the Ryazan Regional Clinical Hospital /ID# 148956
    Ryazan, Ryazanskaya Oblast 390039, Russian Federation
  • LLC Novaya Klinika /ID# 148974
    Pyatigorsk, Stavropol Skiy Kray 357500, Russian Federation
  • Central Clinical Hospital RZHD Medicine /ID# 148954
    Moscow, 129128, Russian Federation
  • Clinical Oncology Dispensary of Omsk /ID# 148953
    Omsk, 644013, Russian Federation
  • Samara State Medical University /ID# 148952
    Samara, 443099, Russian Federation
  • Bashkir State Medical University /ID# 151206
    Ufa, 450008, Russian Federation
  • Hospital Duran i Reynals /ID# 148989
    Hospitalet de Llobregat, Barcelona 08907, Spain
  • Hospital Universitario de la Princesa /ID# 148980
    Madrid, 28006, Spain
  • Hospital Universitario 12 de Octubre /ID# 148981
    Madrid, 28041, Spain
  • Hospital Universitario Dr. Peset /ID# 148986
    Valencia, 46017, Spain
  • Changhua Christian Hospital /ID# 154447
    Changhua City, Changhua County, 50006, Taiwan
  • China Medical University Hospital /ID# 154446
    Taichung City, 40447, Taiwan
  • National Taiwan University Hospital /ID# 154444
    Taipei City, 100, Taiwan
  • Taipei Veterans General Hosp /ID# 154445
    Taipei City, 11217, Taiwan
  • Communal Nonprofit Enterprise Cherkasy Regional Oncology Dispensary /ID# 152414
    Cherkasy, 18009, Ukraine
  • Municipal Non-Profit Enterprise City Clinical Hospital 4 of Dnipro City Council /ID# 152411
    Dnipro, 49102, Ukraine
  • National Cancer Institute /ID# 152413
    Kyiv, 03022, Ukraine
  • Leicester Royal Infirmary /ID# 149057
    Leicester, England LE1 5WW, United Kingdom
  • Barts Health NHS Trust /ID# 149050
    London, London, City Of E1 2ES, United Kingdom
  • Nottingham University Hospitals NHS Trust /ID# 149047
    Nottingham, Nottinghamshire NG5 1PB, United Kingdom
  • Blackpool Teaching Hospitals NHS Foundation Trust /ID# 149058
    Blackpool, FY3 8NR, United Kingdom
  • East Kent Hospitals University NHS Foundation Trust /ID# 149059
    Canterbury, CT1 3NG, United Kingdom
  • University College London Hospitals NHS Foundation Trust /ID# 149044
    London, NW1 2PG, United Kingdom
  • King's College Hospital NHS Foundation Trust /ID# 149045
    London, SE5 9RS, United Kingdom
  • Manchester University NHS Foundation Trust /ID# 149046
    Manchester, M13 9WL, United Kingdom
  • Barking, Havering and Redbridge University Hospitals NHS Trust /ID# 149055
    Romford, RM7 0AG, United Kingdom
  • The Royal Wolverhampton NHS Trust /ID# 149043
    Wolverhampton, WV10 0QP, United Kingdom
09

References and documents

Publications

  • Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, Hungria V, Salwender H, Suzuki K, Kim I, Punnoose EA, Hong WJ, Freise KJ, Yang X, Sood A, Jalaluddin M, Ross JA, Ward JE, Maciag PC, Moreau P. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020 Dec;21(12):1630-1642. doi: 10.1016/S1470-2045(20)30525-8. Epub 2020 Oct 29. PubMed 33129376 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Mar 2021, 56 months.

Results were first posted in Aug 2023, 2 years 5 months after primary completion. A results delay was requested in Jul 2021.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 56 months is above that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2016
First posted
Apr 29, 2016
StartActual
Jul 11, 2016
Primary completionActual
Mar 15, 2021
CompletionActual
Aug 15, 2022
Results delay requested
Jul 16, 2021
Results first posted
Aug 22, 2023
Last update
Aug 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02755597
Lead sponsor
AbbVie
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Apr 29, 2016
Start date
Jul 11, 2016
Primary completion
Mar 15, 2021
Completion
Aug 15, 2022
Results posted
Aug 22, 2023
Last update
Aug 22, 2023

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion